Home › Metastatic Cancer › Colorado › Aurora
Metastatic Cancer clinical trials in Aurora, CO
25 studies for Metastatic Cancer are looking for participants at sites in and around Aurora (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Aurora
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- UCHealth University of Colorado Hospital, Aurora
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RecruitingPhase 1
- University of Colorado Anschutz Medical Campus, Aurora
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- Rocky Mountain Cancer Centers, LLP, Aurora
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Aurora
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
- Children's Hospital Colorado - Anschutz Medical Campus, Aurora
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- Anschutz Cancer Pavilion, Aurora
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- University of Colorado Cancer Center, Aurora
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- Rocky Mountain Cancer Centers,LLP, Aurora
- Clinical and Translational Research Center(CTRC), Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora
- and 2 more
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- University of Colorado Health Hospital, Aurora
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- University of Colorado, Aurora
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University of Colorado, Aurora
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RecruitingPhase 1/2
- Crinetics Study Site, Aurora
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecruitingPhase 1
- University of Colorado - Aurora Cancer Center, Aurora
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- University of Colorado Cancer Center, Aurora
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RecruitingPhase 1/2
- University of Colorado Cancer Center, Aurora
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingPhase 2/3
- University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RecruitingPhase 1/2
- University of Colorado Cancer Center, Aurora
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- University of Colorado Hospital - Anschutz Cancer Pavilion(ACP), Aurora
Venetoclax Basket Trial for High Risk Hematologic Malignancies
RecruitingPhase 1
- Children's Hospital Colorado, Aurora
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- UCHealth Cancer Care - Anschutz Medical Campus, Aurora
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RecruitingPhase 3
- University of Colorado Cancer Center, Aurora
Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis
RecruitingPhase 1
- University of Colorado Cancer Center, Aurora
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Aurora
A Study of NX-1607 in Adults With Advanced Malignancies
RecruitingPhase 1
- University of Colorado School of Medicine, Aurora
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Aurora
- Cancer (all types)35 studies
- Colorectal Cancer32 studies
- Non-Small Cell Lung Cancer31 studies
- Breast Cancer28 studies
- Ovarian Cancer25 studies
- Type 1 Diabetes23 studies
- Obesity22 studies
- Prostate Cancer19 studies
- Lung Cancer19 studies
- Heart Failure18 studies
- Melanoma18 studies
- Acute Myeloid Leukemia16 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.